Dr. Pablo A. González is an Associate professor at the Faculty of Biological Sciences, Pontificia Universidad Católica De Chile, Chile, and an investigator at the Millennium Institute on Immunology and Immunotherapy, a center of excellence recognized as such by the Federation of Clinical Immunology Societies (FOCIS). He completed his Ph.D. in molecular genetics and microbiology at the Pontificia Universidad Católica de Chile in 2008 and then performed a post-doctorate in immune evasion by respiratory viruses. He then served as a research associate at the Howard Hughes Medical Institute (HHMI) at the Albert Einstein College of Medicine, NY, USA, until 2013, where he worked on microbial genetics. He has participated in the direction of several clinical studies for vaccines, including COVID-19 vaccines during the SARS-CoV-2 pandemic. At present, his laboratory is mainly focused on the study of immune evasion by herpes simplex viruses (herpes simplex virus type 1, HSV-1, and herpes simplex virus type 2, HSV-2), which infect epithelial cells, neurons, and immune cells with different effects. He is an author in more than 100 scientific publications.
